CNBC Business News Update Market Close: Stocks Higher, Investors Hopeful Iran War Will Wind Down Soon, FDA Approves Eli Lilly's Weight Loss Pill 4/1/26
Apr 1, 2026
Markets ticked up on hopes of de‑escalation in Iran and its impact on major indexes. Analysts urge caution despite recent gains and flag oil supply shocks driving fuel prices. The FDA cleared Eli Lilly’s new daily weight loss pill, sparking discussion of pricing and efficacy. Mortgage rates cooled spring homebuying, and unusual travel patterns showed more Canadians returning from abroad than visiting the U.S.
AI Snips
Chapters
Transcript
Episode notes
Market Rally Fueled By Iran War Optimism
- Stocks rose on hopes the Iran war will end quickly, lifting the Dow, S&P 500 and Nasdaq during the session.
- Jessica Ettinger reported Boeing led gains with the Dow up 224 points and NVIDIA around $175 a share, signaling tech and industrial strength.
Supply Shock Keeps Oil Elevated Longer
- Oil prices pulled back but gasoline at the pump rose, creating tension between headline crude and consumer pain.
- Mike Santoli and Dan Stryven noted a large supply shock raising the baseline for oil prices, with Goldman Sachs forecasting Q4 prices about $20 higher than pre-war.
Lilly's New Daily Pill Changes Weight Loss Market
- The FDA approved Eli Lilly's daily GLP-1 weight loss pill Foundayo, which ships Monday from Lilly Direct with insurance copay $25 and cash prices $149–$349 monthly.
- CNBC highlighted Foundayo's lower efficacy versus weekly shot Zepbound, with roughly half the weight loss, raising questions about market uptake.